Literature DB >> 15618287

The zinc finger Ikaros transcription factor regulates pituitary growth hormone and prolactin gene expression through distinct effects on chromatin accessibility.

Shereen Ezzat1, Shunjiang Yu, Sylvia L Asa.   

Abstract

The Ikaros transcription factors perform critical functions in the control of lymphohematopoiesis and immune regulation. Family members contain multiple zinc fingers that mediate DNA binding but have also been implicated as part of a complex chromatin-remodeling network. We show here that Ikaros is expressed in pituitary mammosomatotrophs where it regulates the GH and prolactin (PRL) genes. Ikaros was detected by Northern and Western blotting in GH4 pituitary mammosomatotroph cells. Wild-type Ikaros (Ik1) inhibits GH mRNA and protein expression but stimulates PRL mRNA and protein levels. Ikaros does not bind directly to the proximal GH promoter but abrogates the effect of the histone deacetylation inhibitor trichostatin A on this region. Ikaros selectively deacetylates histone 3 residues on the proximal transfected or endogenous GH promoter and limits access of the Pit1 activator. In contrast, Ikaros acetylates histone 3 on the proximal PRL promoter and facilitates Pit1 binding to this region in the same cells. These data provide evidence for Ikaros-mediated histone acetylation and chromatin remodeling in the selective regulation of pituitary GH and PRL hormone gene expression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15618287     DOI: 10.1210/me.2004-0432

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  14 in total

1.  CtBP1 interacts with Ikaros and modulates pituitary tumor cell survival and response to hypoxia.

Authors:  Katie Dorman; Zhongyi Shen; Caimei Yang; Shereen Ezzat; Sylvia L Asa
Journal:  Mol Endocrinol       Date:  2012-02-02

Review 2.  Pathogenesis of pituitary tumors.

Authors:  Shlomo Melmed
Journal:  Nat Rev Endocrinol       Date:  2011-03-22       Impact factor: 43.330

3.  Molecular specification and patterning of progenitor cells in the lateral and medial ganglionic eminences.

Authors:  Eric S Tucker; Samantha Segall; Deepak Gopalakrishna; Yongqin Wu; Mike Vernon; Franck Polleux; Anthony-Samuel Lamantia
Journal:  J Neurosci       Date:  2008-09-17       Impact factor: 6.167

4.  Mechanisms involved in glucocorticoid induction of pituitary GH expression during embryonic development.

Authors:  Laura E Ellestad; Stefanie A Puckett; Tom E Porter
Journal:  Endocrinology       Date:  2015-01-05       Impact factor: 4.736

Review 5.  Genomics and Epigenomics of Pituitary Tumors: What Do Pathologists Need to Know?

Authors:  Sylvia L Asa; Ozgur Mete; Shereen Ezzat
Journal:  Endocr Pathol       Date:  2021-01-12       Impact factor: 3.943

6.  Co-expression of FBN1 with mesenchyme-specific genes in mouse cell lines: implications for phenotypic variability in Marfan syndrome.

Authors:  Kim M Summers; Sobia Raza; Erik van Nimwegen; Thomas C Freeman; David A Hume
Journal:  Eur J Hum Genet       Date:  2010-06-16       Impact factor: 4.246

Review 7.  Recent progress in studies of pituitary tumor pathogenesis.

Authors:  Takeo Minematsu; Shunsuke Miyai; Hanako Kajiya; Masanori Suzuki; Naoko Sanno; Susumu Takekoshi; Akira Teramoto; Robert Y Osamura
Journal:  Endocrine       Date:  2005-10       Impact factor: 3.633

8.  Imprint switch mutations at Rasgrf1 support conflict hypothesis of imprinting and define a growth control mechanism upstream of IGF1.

Authors:  Nadia M Drake; Yoon Jung Park; Aditya S Shirali; Thomas A Cleland; Paul D Soloway
Journal:  Mamm Genome       Date:  2009-06-10       Impact factor: 2.957

9.  An essential role for the hematopoietic transcription factor Ikaros in hypothalamic-pituitary-mediated somatic growth.

Authors:  Shereen Ezzat; Rene Mader; Sandra Fischer; Shunjiang Yu; Cameron Ackerley; Sylvia L Asa
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-07       Impact factor: 11.205

Review 10.  Genomic approaches to problems in pituitary neoplasia.

Authors:  Sylvia L Asa; Shereen Ezzat
Journal:  Endocr Pathol       Date:  2014-09       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.